Dr. Leisha Emens is professor of medicine in hematology/oncology at the University of Pittsburgh Hillman Cancer Center. She is also co-leader of the Hillman Cancer Immunology and Immunotherapy Program and director of translational immunotherapy for the Women’s Cancer Research Center. She is internationally recognized for her work in breast cancer immunotherapy. At the European Society for Medical Oncology 2019 Congress, she presented overall survival results from the KATE2 study, which compared using the combination of Tecentriq, also called atezolizumab, and Kadcyla, also called T-DM1, to Kadcyla alone to treat HER2-positive metastatic breast cancer that had grown while being treated with Herceptin and chemotherapy. Listen to the podcast to hear Dr. Emens discuss: the design of the KATE2 study why the study is encouraging, even though it didn't meet its primary endpoint what the results mean for people diagnosed with HER2-positive metastatic breast cancer her advice to people diagnosed with breast cancer who are interested in immunotherapy

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related